The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, single-ascending dose, phase Ia study to
evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics, and immunogenicity of
STSA-1301 Subcutaneous Injection in healthy subjects.